Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Bharathi, Vanthana [1 ]
Bataller, Alex [2 ]
Bazinet, Alexandre [1 ]
Borthakur, Gautam [3 ]
Jabbour, Elias [1 ]
Daver, Naval [4 ]
Short, Nicholas J. [1 ]
Takahashi, Koichi [1 ]
Issa, Ghayas C. [1 ]
Dinardo, Courtney D. [1 ]
Pemmaraju, Naveen [1 ]
Jain, Nitin [1 ]
Montalban-Bravo, Guillermo [1 ]
Wierda, William G. [2 ]
Ravandi, Farhad [1 ]
Kantarjian, Hagop M. [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX USA
[4] MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-209157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4272 / 4274
页数：3
相关论文
共 50 条
  • [1] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [2] Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan M.
    Borthakur, Gautam
    Takahashi, Koichi
    DiNardo, Courtney D.
    Daver, Naval
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Short, Nicholas J.
    Qiao, Wei
    Adewale, Lade
    Rausch, Caitlin R.
    Pierce, Sherry A.
    Alvarado, Yesid
    Alousi, Amin M.
    Popat, Uday R.
    Khouri, Issa F.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    BLOOD, 2020, 136
  • [3] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
    Kim, Kunhwa
    Kantarjian, Hagop
    Borthakur, Gautam
    Takahashi, Koichi
    Short, Nicholas J.
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Chien, Kelly S.
    Daver, Naval
    Pemmaraju, Naveen
    Jain, Nitin
    Adewale, Lade
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Verstovsek, Srdan
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2021, 138
  • [4] CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia
    Baoligny, Panellan
    Murray, Graeme
    Ho, Thuy
    Gor, Juhi
    Zacholski, Kyle
    Wages, Nolan
    Grant, Steven
    Maher, Keri
    BLOOD, 2023, 142
  • [5] V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.
    Agresta, Laura
    O'Brien, Maureen Megan
    O'Brien, Eric Justin
    Norris, Robin Elizabeth
    Breese, Erin Haag
    Burns, Karen Cristly
    Mizukawa, Benjamin
    Ryan, Thomas D.
    Desai, Pankaj B.
    Vinks, A. A.
    Grimes, H. Leighton
    Absalon, Michael
    Perentesis, John Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Wang, Qi
    Gosselin, Nathalie H.
    Absalon, Michael J.
    Kolb, E. Anders
    Marier, J. F.
    Alonzo, Todd A.
    Faderl, Stefan
    Cooper, Todd M.
    BLOOD, 2020, 136
  • [7] Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
    Jen, Wei-Ying
    DiNardo, Courtney D.
    Chien, Kelly S.
    Alvarado-Valero, Yesid
    Masarova, Lucia
    Brandt, Mark
    Bull-Linderman, Debra
    Daver, Naval
    Montalban-Bravo, Guillermo
    Bataller, Alex
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Alousi, Amin
    Short, Nicholas J.
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [8] CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
    Wang, Qi
    Cooper, Todd M.
    Absalon, Michael J.
    Kolb, E. Anders
    Vasilinin, Grygoriy
    Gosselin, Nathalie H.
    Alonzo, Todd A.
    Marier, J. F.
    BLOOD, 2020, 136
  • [9] A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study
    Wierzbowska, Agnieszka
    Pluta, Agnieszka
    Stelmach, Piotr
    Brzozowski, Kamil
    Czemerska, Magdalena
    Sobas, Marta
    Rybka, Justyna
    Wrobel, Tomasz
    Zarzycka, Ewa
    Prejzner, Witold
    Zaucha, Jan M.
    Szczepaniak, Andrzej
    Gil, Lidia
    Giebel, Sebastian
    BLOOD, 2023, 142
  • [10] Pooled clinical safety analysis of CPX-351 versus conventional chemotherapy in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML)
    Cortes, Jorge E.
    Ryan, Robert J.
    Louie, Arthur C.
    Chiarella, Michael
    Uy, Geoffrey L.
    BONE MARROW TRANSPLANTATION, 2019, 54 : 158 - 158
12345